Vitamin K2 (MK-4).

Tissues convert phylloquinone into menaquinone-4 through the enzyme UBIAD1, so K1 is a direct upstream source of MK-4. Supplying both covers the pathway at two points.

MK-4 clears from circulation within hours while MK-7 stays for days, and both hand electrons to the same gamma-carboxylase. Pairing them gives a peak plus a steady baseline instead of one or the other.

Vitamin D raises production of osteocalcin and matrix Gla protein, and MK-4 carboxylates them so they can hold calcium. The two act in sequence on one substrate.

Carboxylated Gla proteins are the mechanism that routes calcium to bone matrix rather than soft tissue. MK-4 activity therefore determines where a calcium dose is deposited.

Magnesium runs the hydroxylases that activate vitamin D, which in turn sets how much Gla protein there is to carboxylate. Magnesium is also part of the bone crystal itself.

High alpha-tocopherol intakes interfere with the vitamin K quinone cycle and lower carboxylation. A large vitamin E dose alongside MK-4 works against it rather than with it.

MK-4 is fat soluble and needs dietary lipid to enter micelles for uptake. Its short circulating life makes taking it with fat, and with meals, the practical form of this pairing.

The vitamin D receptor pairs with the retinoid X receptor to drive osteocalcin transcription, so retinoid status sets substrate supply. MK-4 then carboxylates what is made.

Ascorbate is the cofactor for collagen hydroxylases that build the protein scaffold mineral attaches to. MK-4 governs mineral placement onto that scaffold.

An oil base raises micellar uptake of menaquinone-4, which is why many MK-4 products are oil suspensions. The effect is on absorption, not on the carboxylation step.

Menaquinone-4 is a fat-soluble prenylated naphthoquinone and requires bile acid micelles to cross the unstirred water layer. Anyone with reduced bile flow absorbs less of any fat-soluble vitamin from the same dose. This is the standard reason vitamin K is dosed with a fat-containing meal.

Pancreatic lipase liberates the fatty acids and monoglycerides that build the mixed micelle carrying fat-soluble vitamins. Without that hydrolysis the oil vehicle in a softgel does not release its cargo efficiently. The dependence is on fat digestion generally, not on MK-4 specifically.

A broad-spectrum digestive enzyme blend contributes lipase alongside protease and amylase, supporting the fat digestion that fat-soluble vitamin uptake depends on. The relevance is greatest where fat digestion is already limited. It is enabling rather than additive: it does not add vitamin K activity of its own.

Lecithin phospholipids emulsify oil droplets and reduce the particle size the gut has to work with, which is why they appear in fat-soluble vitamin softgels. MK-4 is delivered as an oil suspension in most finished products. The role is formulation, and it does not change the vitamin's activity.

Phosphatidylcholine is the principal phospholipid of bile-derived mixed micelles, the vehicle that fat-soluble vitamins ride into the enterocyte. Supplying it alongside supports the same transport step. The effect is on delivery, not on carboxylase activity.

Krill oil delivers fatty acids in phospholipid form, which emulsifies readily and makes an effective carrier for a fat-soluble vitamin in the same capsule. Any fat source in the same meal does much of this work. The relationship is with the fat, not uniquely with krill oil.

Co-ingested long-chain fat raises the absorbed fraction of fat-soluble vitamins by driving bile release and micelle formation. Omega-3 concentrates also carry their own oxidation considerations, which is why they are formulated with a tocopherol. Both EPA/DHA and vitamin K have relevance to clotting physiology, so their combined use is something a prescriber should know about.

Both MK-4 and ubiquinone are prenylated quinones built on isoprenoid side chains derived from the mevalonate pathway. Geranylgeranyl pyrophosphate from that pathway is the prenyl donor for MK-4 synthesis in tissue. The shared origin is real biochemistry; it is not a claim that one raises the other's status.

Ubiquinol is the reduced form of the same prenylated quinone, and its isoprenoid tail comes from the same pathway that supplies the geranylgeranyl group of MK-4. Both are fat-soluble and share a delivery route in an oil vehicle. The commonality is chemical and metabolic origin.

Boron influences calcium and magnesium handling and steroid hormone metabolism in human balance studies. MK-4 acts on the carboxylation status of osteocalcin, a separate node in bone matrix biology. Combining them addresses different steps and the combination has not been trialled.

Zinc is the metal cofactor of alkaline phosphatase, a bone matrix enzyme, and contributes to collagen matrix formation. Vitamin K works on the carboxylation of matrix proteins rather than on mineral chemistry directly. The two act on different stages of the same tissue process.

Manganese is required by the glycosyltransferases that build proteoglycan ground substance in bone and cartilage matrix. That is a distinct requirement from the gamma-carboxylation vitamin K supplies. Both are matrix-side rather than mineral-side contributions.

Silicon has been associated with collagen matrix formation in observational and animal work, and cohort associations with bone density are associations rather than demonstrated causes. Vitamin K acts on Gla protein carboxylation. Pairing them addresses matrix from two angles with different evidence weights.

Bone mineral is calcium phosphate as hydroxyapatite, so phosphorus is a structural requirement alongside calcium. Osteocalcin, the vitamin K-dependent protein of bone, binds hydroxyapatite once carboxylated. The relationship is structural rather than regulatory.

Strontium sits directly below calcium in the periodic table, substitutes for it in hydroxyapatite and competes with it for intestinal absorption. It also inflates bone density readings on DXA because it is denser than calcium, which makes the measurement hard to interpret. That measurement artefact is the most important thing to know about the pairing.

Type I collagen is the protein scaffold that bone mineral deposits onto, and osteocalcin is the vitamin K-dependent non-collagenous protein embedded in it. Supplying amino acid substrate for collagen and supplying the carboxylation cofactor act at different steps. No combination trial exists.

Lysine residues are the substrate for lysyl oxidase, the enzyme that crosslinks collagen fibrils and gives bone matrix its tensile properties. Vitamin K works on glutamate residues in a different protein set. Both are matrix contributions through unrelated chemistry.

High-dose vitamin E has been shown to lower vitamin K status measures, an interaction attributed to competition in absorption and to induction of the enzymes that metabolise vitamin K. Tocotrienols are vitamin E family members and plausibly share that behaviour. Anyone on a vitamin K antagonist medicine should have this interaction on record with their prescriber.

Alpha-tocopherol at supplemental doses has been reported to reduce carboxylation status markers of vitamin K-dependent proteins, most likely through shared absorption and accelerated vitamin K catabolism. The effect is dose-dependent and small at ordinary intakes. It is a marker-level interaction rather than a demonstrated clinical outcome.

Natto is simultaneously the richest food source of menaquinone-7 and the source of nattokinase, a fibrinolytic enzyme, so the two travel together in fermented soy products. Vitamin K supports the carboxylation of clotting factors while a fibrinolytic enzyme acts in the opposite direction on fibrin. Anyone on anticoagulant medicine needs both of these on the record with the prescriber.

Gut bacteria including Bacteroides species synthesise long-chain menaquinones, and Bacillus subtilis natto produces MK-7 during fermentation. How much colonic menaquinone actually contributes to human vitamin K status remains unsettled because absorption from the colon is limited. Read the pairing as plausible and unresolved.

Fat-soluble compounds compete for space in a limited number of mixed micelles when taken together at high doses. That competition is documented among carotenoids and between carotenoids and fat-soluble vitamins. The effect at ordinary supplement doses in a fat-containing meal is likely to be small.